title: Toward the optimization of stent-based treatment for coronary artery disease.
abstract: Coronary artery disease consists of obstruction (stenosis) of the coronary arteries by the deposition of atherosclerotic plaques, resulting in an insufficient supply of oxygen to the heart muscle. Treatment options include the insertion of a stent - a metal mesh tube - into the obstructed vessel to keep the artery open, thus preventing acute occlusion and restenosis. The occlusion of vessels resulting from subacute stent thrombosis and late in-stent restenosis are potential complications after successful revascularization. However, the rate of stent thrombosis has been reduced dramatically by means of adequate antiplatelet therapy, and in-stent restenosis has been addressed successfully with drug-eluting stents. These drug-eluting stents are engineered to release bioactive agents into the affected blood vessels, plaques or tissues adjacent to the stent. Various antimitotic, anti-inflammatory, and anticoagulant immunosuppressive agents have been attached to stents, including sirolimus and tacrolimus. Future opportunities include the use of gene therapies released from gene-eluting stents. These advances highlight some of the opportunities for optimizing stent-based treatment for coronary artery disease.
authors.affiliation: Celgene International Sàrl, Route de Perreux 1, 2017 Boudry, Switzerland. aromano@celgene.com
authors.forename: Alfredo
authors.initials: A
authors.lastname: Romano
authors.forename: Michael Rugaard
authors.initials: MR
authors.lastname: Jensen
authors.forename: Jim
authors.initials: J
authors.lastname: McAlpine
mesh_terms: D003324:Coronary Artery Disease / Q000628:therapy*; D004337:Drug Carriers / Q000627:therapeutic use; D054855:Drug-Eluting Stents; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D004337:Drug Carriers; D010975:Platelet Aggregation Inhibitors